FDA Authorizes Merck's At-Home Covid-19 Pill

Summary

Podcast Summary: WSJ Your Money Briefing

Episode: FDA Authorizes Merck's At-Home Covid-19 Pill
Date: December 23, 2021
Host: JR Whalen (The Wall Street Journal)

---

Episode Overview

This episode of "WSJ Your Money Briefing" provides a concise update on several major headlines relevant to personal finance and global affairs. The main focus is on the FDA's authorization of Merck's at-home Covid-19 treatment pill, with additional highlights on economic data such as consumer spending and U.S. unemployment claims, and a brief update on geopolitical tensions between Russia, Ukraine, and the West.

---

Key Discussion Points & Insights

1. FDA Clears Merck's At-Home Covid-19 Pill

• Announcement:
  The Food and Drug Administration (FDA) has authorized an at-home Covid-19 pill by Merck and Ridgeback Biotherapeutics.
• Usage:
  The antiviral pill can now be prescribed by doctors to adults who are at high risk of developing severe Covid-19 symptoms, to be used shortly after mild to moderate symptoms appear.
• Related News:
  Earlier in the same week, the FDA also cleared a similar Covid-19 pill produced by Pfizer.

Quote:

• JR Whalen:

  "An at home COVID 19 pill from drug makers Merck and partner Ridgeback Biotherapeutics has been cleared for use by the Food and Drug Administration." (00:18)

---

2. Economic Data Update

a. Consumer Spending

• Statistics:
  Consumer spending rose by 0.6% in November, which is a slower pace compared to October.
• Insight:
  The slower increase is attributed to consumers shopping earlier than usual, likely due to concerns about product shortages during the holiday season.

Quote:

• JR Whalen:

  "Consumer spending rose 0.6% in November. That's less than October's pace, when holiday shoppers snatched up gifts earlier than usual in anticipation of product shortages." (00:41)

b. Jobless Claims

• Latest Figures:
  Worker filings for unemployment benefits remain at the lowest level in over 50 years.
• Labor Market:
  Initial jobless claims last week were steady at 205,000, reflecting enduring labor market strength with layoffs remaining low.

Quote:

• JR Whalen:

  "Worker filings for unemployment benefits are hovering at the lowest level in more than half a century... The Labor Department says initial jobless claims last week held steady at 205,000 as a strong labor market kept layoffs low." (00:53)

---

3. International Update: Russia & Ukraine

• Russian President Vladimir Putin's Statement:
  At his annual news conference, President Putin denied intentions for conflict with Ukraine or the West. He accused Western nations of fostering anti-Russia sentiment and cited the need to protect Russian sovereignty due to perceived NATO threats.

Quote:

• JR Whalen:

  "Russian President Vladimir Putin denied that his country is seeking conflict with Ukraine and the West. He accused the west of stoking anti Russia sentiment in Ukraine and defended the need to protect his country's integrity and sovereignty against what he described as attempts by NATO to encroach on Russia's doorstep." (01:04)

---

Notable Moments & Quotes

• FDA Authorization:
  JR Whalen:

  "Doctors will be able to prescribe the drug to adults at high risk of severe disease shortly after they develop mild to moderate symptoms." (00:27)

• Labor Market Health:
  JR Whalen underscores the remarkable state of unemployment claims, emphasizing their historic low point and reflecting overall economic resilience. (00:53–01:04)

---

Timed Highlights

• 00:18 – FDA authorizes Merck’s at-home Covid-19 pill
• 00:41 – Consumer spending data for November
• 00:53 – U.S. jobless claims at historic lows
• 01:04 – Vladimir Putin’s annual press conference and Russia/Ukraine tensions

---

Conclusion

This episode provides listeners with a succinct roundup of important news impacting health, personal finance, and global affairs. Of particular note is the FDA's approval of Merck's at-home Covid-19 pill, signaling a new phase in at-home treatments for the pandemic, alongside continued resilience in the U.S. economy.

---

Note: This summary omits advertisements and non-content segments per the provided guidelines.

Transcript

[JR Whalen]

Deal

[Podcast Host/Announcer]

replaces fragmented payroll vendors with one global system. No third parties hire, manage and pay teams in 150 plus countries. Operate like a local everywhere. Visit d eel.com WSJ

[JR Whalen]

here's your midday brief for Thursday, December 23rd. I'm JR Whalen. For the Wall Street Journal, an at home COVID 19 pill from drug makers Merck and partner Ridgeback Biotherapeutics has been cleared for use by the Food and Drug Administration. Doctors will be able to prescribe the drug to adults at high risk of severe disease shortly after they develop mild to moderate symptoms. This week, the FDA also cleared a Covid pill from Pfizer. The Commerce Department says consumer spending rose 0.6% in November. That's less than October's pace, when holiday shoppers snatched up gifts earlier than usual in anticipation of product shortages. Meanwhile, worker filings for unemployment benefits are hovering at the lowest level in more than half a century. The Labor Department says initial jobless claims last week held steady at 205,000 as a strong labor market kept layoffs low. And in his annual news conference with world reporters, Russian President Vladimir Putin denied that his country is seeking conflict with Ukraine and the West. He accused the west of stoking anti Russia sentiment in Ukraine and defended the need to protect his country's integrity and sovereignty against what he described as attempts by NATO to encroach on Russia's doorstep. We'll have a lot more coverage of the day's news on the WSJ's what's News podcast. You can add it to your playlist on your smart speaker or listen and subscribe wherever you get your podcasts.

[Podcast Host/Announcer]

This podcast is brought to you by reliaQuest. Cybercriminals are constantly attacking. They want your data. They want your identity. They want your innovation. ReliaQuest fortifies your business with agentic defense AI that detects, contains and eliminates cyber threats in minutes. It helps your security team move faster at the work that matters most to protect the business now and and delivers insights to help them predict what's next. ReliaQuest agentic defense for the enterprise learn more at reliaquest.com that's R E L I A Q U E-S-T dot com.